Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04605614
Title 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center

hematologic cancer

Advanced Solid Tumor



Age Groups: adult | senior
Covered Countries

Facility Status City State Zip Country Details
*Shaded cells indicate that there was no data available from for the field